{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:57:51Z","timestamp":1790121471350,"version":"4.0.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.gtc.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:18:13Z","timestamp":1762539493000},"page":"185-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1016","volume":"55","author":[{"given":"Arka","family":"De","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.gtc.2025.09.003_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.gtc.2025.09.003_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gtc.2025.09.003_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jceh.2019.09.005","article-title":"Natural history of simple steatosis or nonalcoholic fatty liver","volume":"10","author":"De","year":"2020","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2025.09.003_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.gtc.2025.09.003_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2025.09.003_bib6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gtc.2025.09.003_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102590","article-title":"Adoption of the new nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Indian National Association for Study of the Liver (INASL): implications for the INASL guidance paper on NAFLD","volume":"15","author":"Duseja","year":"2025","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2025.09.003_bib8","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1016\/j.jhep.2024.05.027","article-title":"Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: an analysis of the Indian Consortium on MASLD (ICOM-D) cohort","volume":"81","author":"De","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.gtc.2025.09.003_bib9","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.gtc.2025.09.003_bib10","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2025.09.003_bib11","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.jhep.2023.09.033","article-title":"Transitioning from NAFLD to MAFLD and MASLD: consistent prevalence and risk factors in a Chinese cohort","volume":"80","author":"Yang","year":"2024","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.gtc.2025.09.003_bib12","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/gutjnl-2020-321299","article-title":"Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology","volume":"69","author":"Neuberger","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.gtc.2025.09.003_bib13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2025.09.003_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","article-title":"AASLD practice guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gtc.2025.09.003_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD practice guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2025.09.003_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.gtc.2025.09.003_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian National Association for Study of the Liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD)","volume":"13","author":"Duseja","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.gtc.2025.09.003_bib18","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.gtc.2025.09.003_bib19","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.241171","article-title":"Diagnostic accuracy of CT for the detection of hepatic steatosis: a systematic review and meta-analysis","volume":"313","author":"Haghshomar","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.gtc.2025.09.003_bib20","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRIPDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease:a meta-analysis","volume":"29","author":"Gu","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.gtc.2025.09.003_bib21","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2025.09.003_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2025.09.003_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/hep.29489","article-title":"Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease","volume":"67","author":"Vuppalanchi","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2025.09.003_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using M and XL probes: an individual patient meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2025.09.003_bib25","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2025.09.003_bib26","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.gtc.2025.09.003_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238717","article-title":"Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.gtc.2025.09.003_bib28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/j.gastro.2017.01.015","article-title":"Metabolomic identification of subtypes of nonalcoholic steatohepatitis","volume":"152","author":"Alonso","year":"2017","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.gtc.2025.09.003_bib29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep4.1188","article-title":"Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.gtc.2025.09.003_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.gtc.2025.09.003_bib31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ueg2.12589","article-title":"One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population","volume":"12","author":"Iruzubieta","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gtc.2025.09.003_bib32","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/apt.14621","article-title":"Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH","volume":"47","author":"Boursier","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2025.09.003_bib33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.gtc.2025.09.003_bib34","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/gutjnl-2022-328689","article-title":"Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"72","author":"Ravaioli","year":"2023","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.gtc.2025.09.003_bib35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jceh.2021.06.008","article-title":"FibroScan-AST (FAST) score for nonalcoholic steatohepatitis - validation in an Indian cohort","volume":"12","author":"De","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"10.1016\/j.gtc.2025.09.003_bib36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/hep.30483","article-title":"The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in Obese patients undergoing bariatric surgery","volume":"71","author":"Allen","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gtc.2025.09.003_bib37","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/HEP.0000000000000417","article-title":"Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH","volume":"78","author":"Li","year":"2023","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.gtc.2025.09.003_bib38","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jgh.16589","article-title":"Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis","volume":"39","author":"Qi","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2025.09.003_bib39","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jhep.2022.07.020","article-title":"Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD","volume":"77","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2025.09.003_bib40","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2025.09.003_bib41","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.gtc.2025.09.003_bib42","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1007\/s10620-023-08085-y","article-title":"Poor performance of non-invasive tests for advanced fibrosis in nonalcoholic fatty liver disease: a multicentric Asian Study","volume":"68","author":"Arora","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2025.09.003_bib43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2025.09.003_bib44","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2025.09.003_bib45","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/apt.15529","article-title":"Direct comparison of the specialised blood fibrosis tests FibroMeter(V2G) and enhanced liver fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres","volume":"50","author":"Guillaume","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2025.09.003_bib46","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2025.09.003_bib47","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2025.09.003_bib48","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2025.09.003_bib49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: october 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gtc.2025.09.003_bib50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hep.29179","article-title":"Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis","volume":"67","author":"Herrmann","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.gtc.2025.09.003_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021787","article-title":"Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"8","author":"Jiang","year":"2018","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.gtc.2025.09.003_bib52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2025.09.003_bib53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/apt.14219","article-title":"Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD","volume":"46","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.gtc.2025.09.003_bib54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","article-title":"Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based agile scores","volume":"78","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2025.09.003_bib55","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/HEP.0000000000000694","article-title":"Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"79","author":"Dalbeni","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2025.09.003_bib56","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/dom.16142","article-title":"Diagnostic accuracy of Agile-4 score for liver cirrhosis in patients with metabolic dysfunction-associated steatotic liver disease. A systematic review and meta-analysis of diagnostic test accuracy studies","volume":"27","author":"Malandris","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.gtc.2025.09.003_bib57","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2025.09.003_bib58","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jhep.2016.04.023","article-title":"Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease","volume":"65","author":"Boursier","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2025.09.003_bib59","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2025.09.003_bib60","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2025.09.003_bib61","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/liv.14301","article-title":"Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease","volume":"40","author":"Shili-Masmoudi","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.gtc.2025.09.003_bib62","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstr\u00f6m","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2025.09.003_bib63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","article-title":"Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD","volume":"81","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"issue":"15","key":"10.1016\/j.gtc.2025.09.003_bib64","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2025.09.003_bib65","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.cgh.2022.08.036","article-title":"Clinical utility of combined MRI-PDFF and ALT response in predicting histologic response in nonalcoholic fatty liver disease","volume":"21","author":"Huang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2025.09.003_bib66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.12352","article-title":"Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis","volume":"38","author":"Hoofnagle","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2025.09.003_bib67","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/hep4.1680","article-title":"Relationship of ELF and PIIINP with liver histology and response to vitamin E or pioglitazone in the PIVENS trial","volume":"5","author":"Gawrieh","year":"2021","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.gtc.2025.09.003_bib68","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/HEP.0000000000000891","article-title":"Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients","volume":"81","author":"Wong","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2025.09.003_bib69","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/j.gastro.2023.06.030","article-title":"Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease","volume":"165","author":"Semmler","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2025.09.003_bib70","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2025.09.003_bib71","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","author":"Stine","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2025.09.003_bib72","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gtc.2025.09.003_bib73","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep.32545","article-title":"The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care","volume":"77","author":"Sripongpun","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gtc.2025.09.003_bib74","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/apt.17891","article-title":"Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - the gut and obesity in Asia (GO-ASIA) study","volume":"59","author":"Verma","year":"2024","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855325000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855325000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:12:26Z","timestamp":1769184746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855325000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0889855325000664"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2025.09.003","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}